Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that its clinical research operations in Belfast, Northern Ireland UK, and its clinical research and bioanalytical services operations in Lincoln, Nebraska USA, have been certified by the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária - ANVISA).
ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market. ANVISA-certified service providers are uniquely qualified to help clients clear a key hurdle to access one of the fastest-growing major pharmaceutical markets in the world.
"The approval of ANVISA continues to demonstrate the high quality work done at Celerion," said Susan Thornton, President and CEO. "By earning ANVISA certification to conduct early clinical studies and bioanalytical research for compounds destined for Brazil, Celerion is now able to better serve our clients' growing needs in this high-growth, emerging market."
In addition to ANVISA certification, Celerion's Belfast, facility has also been certified by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The facility has received both Standard and Supplementary Accreditation from the MHRA, which certifies that the general standards for study participant safety and access to emergency medical response have been met. The MHRA accreditation attests to Celerion's commitment to participant safety.
Research shows brain synchronization between humans and dogs